Company
Every investor coverage indicates participated in a round CSL Behring raised.
Companies CSL Behring acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Charmaine Gittleson | Chief Medical Officer (former) | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Stories naming CSL Behring. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
George Medicines, a George Institute spin-out developing combination blood pressure therapies, has appointed former CSL Behring chief medical officer Dr Charmaine Gittleson as an independent non-executive director as its drug GMRx2 enters Phase III trials.
Drug developer George Medicines has added Dr Charmaine Gittleson to its board as an independent non-executive director, bringing pharma and CSL Behring leadership experience as its hypertension candidate GMRx2 advances through Phase III trials.